MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)

Supplemental Digital Content is available in the text

Burnout among surgeons before and during the SARS-CoV-2 pandemic: an international survey

Background: SARS-CoV-2 pandemic has had many significant impacts within the surgical realm, and surgeons have been obligated to reconsider almost every aspect of daily clinical practice. Methods: This is a cross-sectional study reported in compliance with the CHERRIES guidelines and conducted through an online platform from June 14th to July 15th, 2020. The primary outcome was the burden of burnout during the pandemic indicated by the validated Shirom-Melamed Burnout Measure. Results: Nine hundred fifty-four surgeons completed the survey. The median length of practice was 10 years; 78.2% included were male with a median age of 37 years old, 39.5% were consultants, 68.9% were general surgeons, and 55.7% were affiliated with an academic institution. Overall, there was a significant increase in the mean burnout score during the pandemic; longer years of practice and older age were significantly associated with less burnout. There were significant reductions in the median number of outpatient visits, operated cases, on-call hours, emergency visits, and research work, so, 48.2% of respondents felt that the training resources were insufficient. The majority (81.3%) of respondents reported that their hospitals were included in the management of COVID-19, 66.5% felt their roles had been minimized; 41% were asked to assist in non-surgical medical practices, and 37.6% of respondents were included in COVID-19 management. Conclusions: There was a significant burnout among trainees. Almost all aspects of clinical and research activities were affected with a significant reduction in the volume of research, outpatient clinic visits, surgical procedures, on-call hours, and emergency cases hindering the training. Trial registration: The study was registered on clicaltrials.gov "NCT04433286" on 16/06/2020

Frattura di femore, quando il timing fa la differenza tra la cura e la morte

Una persona fragile (paziente di 88 anni) cade accidentalmente soccorsa viene predisposta operazione che verrà rinviata per 4 giorni. Dopo intervento e riabilitazione la signora decede. Scongiurata la responsabilità penale, i medici devono rispondere di responsabilità morale, penale, civile e deontologica

Danno complesso alla spalla determinato da infortuni ed errore professionale

La valutazione delle varie condotte teraputiche che si sono succedute nel caso in esame mettono in risalto i risultati positivi e non nel trattamento

Development of uranium carbide targets for the on-line production of neutron-rich isotopes

ACCA number of on-line and off-line tests have been performed at the IRIS (investigation of radioactive isotopes at synchrocyclotron) facility in order to develop uranium carbide targets with a high density (11 g/cm3) for the on-line production of neutron-rich isotopes by fission of $^{238}$U. A 1 GeV proton beam was used to bombard two kinds of targets held at temperatures in the range of 1900–2100 °C. The first one was a target-ion source assembly slightly modified to withstand 3 months of continuous heating at a temperature of about 2050 °C. The second unit was of a new kind, where ionisation takes place in the target volume itself. A comparison of the on-line isotopic yields before and after heating for 3 months is here reported. The yields and release times of Rb, Cs and In are compared with the ones obtained from a standard reference target, as measured in previous experiments

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult-to-treat population, where no standard therapy exists. We evaluated outcomes in patients with first relapsed-refractory (r/r) MCL after upfront high dose cytarabine including standard regimens. Overall survival (OS-2) and progression-free survival (PFS-2) were estimated from the time of salvage therapy. The previously described threshold of 24 months was used to define patients as early- or late-progressors (POD). Overall, 261 r/r MCL patients were included. Second-line regimens consisted of rituximab-bendamustine (R-B, 21%), R-B and cytarabine (R-BAC, 29%), ibrutinib (19%), and others (31%). The four groups were balanced in terms of clinicopathological features. Adjusting for age and early/late-POD, patients treated with R-BAC had significantly higher complete remission (63%) than comparators. Overall, Ibrutinib and R-BAC were associated with improved median PFS-2 [24 and 25 months, respectively], compared to R-B (13) or others (7). In patients with early-POD (n = 127), ibrutinib was associated with inferior risk of death than comparators (HR 2.41 for R-B, 2.17 for others, 2.78 for R-BAC). In patients with late-POD (n = 134), no significant differences were observed between ibrutinib and bendamustine-based treatments. Ibrutinib was associated with improved outcome in early-POD patients